Goldman Sachs Maintains Buy on Teladoc Health, Lowers Price Target to $10

Benzinga · 05/01 17:53
Goldman Sachs analyst David Roman maintains Teladoc Health (NYSE:TDOC) with a Buy and lowers the price target from $13 to $10.